Pemetrexed

Generic Name: Pemetrexed

Brand Names: Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁N_₅O_₆

CAS Number: 137281-23-3

Unique Ingredient Identifier: 04Q9AIZ7NO

Background: Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.

Indication: Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions: Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma

Associated Therapies: Monotherapy

Clinical Trials

A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

Phase 3

Completed

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Interventions: Drug: Bevacizumab
Drug: Erlotinib
Drug: Docetaxel
Drug: Pemetrexed

First Posted Date: 2011-05-10

Last Posted Date: 2017-09-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 485

Registration Number: NCT01351415

Locations: 🇺🇸
University of Pennsylvania; Radiation Oncology, Philadelphia, Pennsylvania, United States
🇯🇵
Miyagi Cancer Center; Respiratory Medicine, Miyagi, Japan
🇺🇸
USA Mitchell Cancer Institute, Mobile, Alabama, United States

and more 176 locations

Pemetrexed as Salvage Treatment in Squamous Cell Carcinoma of Head and Neck

Phase 2

Conditions: Squamous Cell Carcinoma of Head and Neck

Interventions: Drug: Pemetrexed

First Posted Date: 2011-04-12

Last Posted Date: 2013-03-05

Lead Sponsor: Fudan University

Target Recruit Count: 32

Registration Number: NCT01333696

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population

Phase 2

Terminated

Conditions: Lung Cancer, Small Cell

Interventions: Drug: pazopanib
Drug: pemetrexed

First Posted Date: 2011-03-14

Last Posted Date: 2014-10-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 20

Registration Number: NCT01313663

Locations: 🇺🇸
GSK Investigational Site, Vancouver, Washington, United States

A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors

Phase 1

Completed

Conditions: Solid Cancers

Interventions: Drug: GDC-0980
Drug: bevacizumab
Drug: carboplatin
Drug: cisplatin
Drug: paclitaxel
Drug: pemetrexed

First Posted Date: 2011-02-23

Last Posted Date: 2016-11-02

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 75

Registration Number: NCT01301716

C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: LY2603618
Drug: Pemetrexed
Drug: Gemcitabine

First Posted Date: 2011-02-15

Last Posted Date: 2019-01-07

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 3

Registration Number: NCT01296568

Locations: 🇨🇭
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bruderholz, Switzerland

A Study of LY2090314 in Patients With Advanced or Metastatic Cancer

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: LY2090314
Drug: pemetrexed
Drug: Carboplatin
Other: ranitidine

First Posted Date: 2011-02-01

Last Posted Date: 2019-02-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 41

Registration Number: NCT01287520

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashville, Tennessee, United States

TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer

Phase 3

Terminated

Conditions: Carcinoma, Non Small Cell Lung

Interventions: Drug: Taxotere
Drug: Pemetrexed

First Posted Date: 2011-01-24

Last Posted Date: 2015-07-14

Lead Sponsor: Chonnam National University Hospital

Target Recruit Count: 148

Registration Number: NCT01282151

Locations: 🇰🇷
Chonnam National University Hwasun Hospital, Hwasun, Jeonnam, Korea, Republic of
🇰🇷
Kyungpook National University Medical Center, Daegu, Kyungpook, Korea, Republic of
🇰🇷
Hallym University Medical Center, Anyang, Korea, Republic of

and more 12 locations

BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Carboplatin
Drug: Pemetrexed
Drug: Bevacizumab
Drug: Cixutumumab

First Posted Date: 2010-12-21

Last Posted Date: 2019-05-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 64

Registration Number: NCT01263782

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Study in Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small-Cell Lung Carcinoma

Interventions: Drug: Pemetrexed
Drug: Cisplatin
Drug: Cixutumumab

First Posted Date: 2010-11-02

Last Posted Date: 2019-09-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 172

Registration Number: NCT01232452

Locations: 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zeytinburnu, Turkey

A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung

Phase 2

Completed

Conditions: Adenocarcinoma of the Lung

Interventions: Biological: Farletuzumab
Other: Placebo
Drug: Carboplatin
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2010-10-11

Last Posted Date: 2020-08-20

Lead Sponsor: Morphotek

Target Recruit Count: 130

Registration Number: NCT01218516

Locations: 🇺🇸
Clinical Trials and Research Associates, Inc., Montebello, California, United States
🇺🇸
Medical Specialists of the Palm Beaches, Deerfield Beach, Florida, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

and more 90 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy